desensitization remained less as compared to healthy subjects. The extent of desensitization was correlated (r = -0.48, P = .02) with the density (Bmax) of the a2-adrenoceptor high-affinity state, as detected in undesensitized platelet membranes by p125I-clonidine binding. An elevation was also observed in the density of nonadrenergic p125I-clonidine-binding sites (putative imidazoline II sites) in platelet membranes from depressed patients compared to healthy control subjects. Following treatment with desipramine, the patients (n = 15) displayed more normal (nonblunted) extents of desensitization of aggregation, and the Bmax values for the putative II sites were at the levels of healthy controls. If similar aberrations exist in neurons of depressed patients, this may explain a dysregulation of the noradrenergic system believed to underlie depression. [Neuropsycho pharmacology 9:55-66, 1993J 1987). An autoinhibitory role for presynaptic a2-adreno ceptors is of particular interest to the study of depres sion because reduced monoaminergic function has been postulated to underlie depression (Bunney and Davis 1965; Schildkraut 1965; Meana et al. 1992) . Idazoxan, an a2-adrenoceptor antagonist is an effective anti depressant (Osman et al. 1989) , suggesting the pres ence of supersensitive a2-adrenoceptors in depression. Meana and coworkers (Meana et al. 1992 ) have also shown that both the density and affini ty of high-affini ty state a2-adrenoceptors are elevated in certain brain regions of suicide victims with histories of depression. Furthermore, most current concepts regarding mecha nism(s) of action of antidepressant treatments invoke dysfunction of central noradrenergic receptors (Char-ney et a1. 1981; Sulser 1984) . Downregulation of a2-adrenoceptors has been implicated during chronic antidepressant therapy (Vetulani and Antkiewicz Michaluk 1985; Finberg 1987) .
Regarding peripheral measurements, platelet ra dioligand-binding density (Brnax) for high-affinity state a2-adrenoceptors has been reported by us (Piletz et a1. 1990 (Piletz et a1. , 1991 and others (Garcia-Sevilla et a1. 1981 ; reviewed in Werstiuk et a1. 1992 ) to be elevated in depressed patients. Several laboratories (reviewed in Piletz et al., 1991) have additionally reported that the Brnax of high-affinity state radio ligand binding to plate let a2-adrenoceptors declines following successful an tidepressant treatment of depressed patients (Garcia Sevilla et a1. 1981 Healy et a1. 1983; Pandey et al., 1989) . Other groups have failed to detect a decline in a2-adrenoceptor binding with treatment (reviewed in Werstiuk et al. 1992) . Platelet a2-adrenoceptors have further been reported to be supersensitive in depressed patients with regard to epinephrine-induced aggre gation (Garcia-Sevilla et a1. 1990 ) and epinephrine induced phosphoinositide responses (Mori et a1. 1991) , but not with epinephrine-mediated inhibition of ade nylate cyclase (Garcia-Sevilla et a1. 1990 ). Thus, a con siderable body of literature implicates platelet a2-adrenoceptor supersensitivity in depression.
Most previous positive reports of increased a2-adrenoceptor density in depression have utilized ago nist radioligand-binding assays. 3H-Agonists label predominantly the high-affinity state of a2-adreno ceptors that are coupled to guanine nucleotide binding regulatory proteins (G-proteins) (Hoffman and Lef kowitz 1980; Thomsen et a1. 1988; reviewed in Kafka and Paul 1986; Piletz et a1. 1991) . 3H-Antagonists, on the other hand, have not shown differences at the a2-adrenoceptor in depression, and these agents label both high-and low-affinity states of the a2-adrenoceptor (Asakura et a1. 1985) . Based on these radioligand bind ing differences, Garcia-Sevilla et a1. (1986) have hy pothesized that enhanced coupling of the high-affinity a2-adrenoceptor state might underlie receptor super sensitivity in depression.
Dysregulation of the a2-adrenoceptor was pro posed as the dominant factor in the "Dysregulation The ory of Depression" as put forward by Siever and Davis (1985) . Under this theory it was postulated that altered a2-adrenoceptor regulation might manifest as an erratic or unstable nor adrenergic system, for which there is considerable evidence in depressed patients (Siever and Davis 1985; Gwirtsman et al. 1989) . One important level of receptor regulation is desensitization. After pro longed exposure of target cells to hormones or neu rotransmitters, the subsequent receptor-mediated re sponses evoked by agonists are often observed to be attenuated or desensitized. In the best studied exam ple of this, the desensitization of �-adrenoceptors was NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.1 shown to initially involve uncoupling of an active recep tor state formed between the receptor and the G-p rotein (Sibley and Lefkowitz 1985) . Subsequently, receptor un· coupling is followed by receptor phosphorylation and receptor internalization leading to downregulation (Sibley and Lefkowitz 1985; Bouvier et a1. 1988) .
Previous studies have demonstrated that preincu· bation of un stirred platelets with an a2-adrenoceptor agonist (i. e., epinephrine or clonidine) will desensitize in vitro the subsequent aggregation when platelets are rechallenged and stirred (Cooper et a1. 1978; Brodde et a1. 1982; Hollister et a1. 1983; Motulsky et a1. 1986 (Hal· lister et a1. 1983) . Furthermore, desensitization of epi· nephrine-initiated platelet aggregation may be physio logically important because this process has been demonstrated in vivo to exist in response to acute infu· sions of norepinephrine (Jones et a1. 1986; Hamilton et a1. 1987) .
In the present study, we have sought to dete rmine if epinephrine-initiated desensitization might differ in depressed patients relative to healthy controls in vitro. Speci&cally, we have utilized the well-documented phenomena of desensitization of platelet a2-adreno ceptor-mediated aggregation in vitro (Mutulsky et�. 1986 ) to monitor platelet a2-adrenoceptor desensitiza tion in patients and controls. Thereby, we provide, for the first time, evidence that depressed patients might differ from healthy subjects in regard to their intrinsic ability to desensitize an a2-adrenoceptor-mediat edre sponse.
METHODS

Blood Collections
All patients and healthy control subjects gave written informed consent prior to entry into the study. Su� jects were required to observe restrictions on diet and activity for 3 days preceding the blood collections (Pilei! et a1. 1990 ). The use of medication(s) was limited to items not known to affect platelet function and was per. mitted only if the subject had been receiving !hi particular medication for at least 3 months without in terruption. Aside from the specifIed desipramine treatment study (described below), the following"ex!rl medications" were allowed. Two subjects were receiv ing antihypertensive medications (one was recei� captopril and another was receiving enalapril maleate �us diazoxide). Three subjects were using antihista mines (one used cimetidine and two used seldane). Three subjects were using progesterones. One subject Iras using ibuprofen along with sudafed. One subject was using prednisone. One subject was using phenyl propanolamine. Another subject was using low-dose antibiotics. Blood samples were collected throughout ilseasons of the year in an effort to minimize possible !faSOnal variation between groups. Subjects reported klthe outpatient clinic at 8:30 AM. An indwelling 18-sauge angiocatheter was inserted into the anticubital vein with a heparin lock and subjects then rested in a supine po sition for at least 10 minutes prior to blood drawing which occurred between 9:00 and 10:00 AM.
In most cases, the blood drawing procedure oc cmred in four steps, with the exception that a subset .subjects (described below) had blood drawn only for the aggregation measurements.
(1) The fIrst 3 ml of blood was discarded to avoid tissue thromboplastin.
121 An additional 10 ml of blood was then collected into Ivacutainer with heparin (20 Vlml) on ice for analysis • plasma ca techolamines. (3) An additional 100 ml of blood was then collected for radioligand-binding mea turements into two plastic 50-cc syringes and mixed vith heparin (20 V/ml blood) to prevent coagulation. �)Anadditional 27 ml of blood was collected for aggre ,mon measurements and diluted with 3 ml of CPD (2.63% sodium citrate, 0.33% citric acid, 0.22% sodium pIKlsphate, 2.55% dextrose) to prevent coagulation. Be CJUSeplatelet aggregation is influenced by the release • citrate from red blood cells during centrifugation (Ts'ao et al. 1976) , we compensated for differences in drate concentration that would be expected based on mying hematocrits between samples. This was accom plMed by obtaining the hematocrit, and then further adjusting the sodium citrate concentration of each blood IIIIP le to that found in blood with a hematocrit of 50, ,mto the aggregation measurements according to the bmulations of Ts'ao et a1. (1976) and Kelton et al. �). All platelet preparatory procedures were con �ed in plastic tubes kept at room temperature. Pssma obtained from each subject was stored at -80DC lid later thawed for the assay of catecholamine con llll lra tions using high-performance liquid chromatog aphy with a Coulochem detector (ESA Corp., Bedford, MA), as described by Mefford (1981) .
enrol Subjects
PIospective healthy subjects underwent an interview Wha psychiatric nurse and a psychiatrist to establish fI1ysical and mental health (Piletz et a1. 1990 ). Healthy IIbjects reported no personal or family history of psy dlitric ill ness among fIrst-degree relatives, and none illka ted a history of alcohol or drug abuse. Healthy Delayed Desensitization in Depression 57 subjects were paid for their participation. For the aggre gation measurements, there were 17 females and eight males in our healthy subject group, with an overall age of 36.6 ± 8.5 (SD) years. Fifteen of those healthy sub jects (11 females, four males) had additional platelets collected at the same time for measurements of radio ligand binding and plasma catecholamine concentra tions.
Patients
Patients were recruited through hospital referrals and treated as outpatients. Depressed patients (n = 22) met Research Diagnostic Criteria (RDC) for primary major depression, unipolar subtype. Diagnoses were made by one of two experienced psychiatrists during a com prehensive intake interview. The kappa coefficient for interrater reliability was 0.82. The severity of depres sion was evaluated using the Hamilton Depression Rat ing Scale (HDRS) (Hamilton 1967) . For epinephrine initiated platelet aggregation measurements, the depressed patient group was composed of 15 females and seven males, with an overall age of 42.5 ± 11.4 years. Among the depressed patients a subset of 10 fe males and six males had additional platelets collected for the additional radioligand binding and plasma cate cholamine measurements. To study the effects of treat ment, 15 depressed patients were restudied for platelet aggregation after 6 weeks of treatment with desipra mine (composed of eight females and seven males). Four other patients dropped out of the study before completing treatment, and three other patients were discontinued early due to adverse side effects of desi pramine. The overall age of the patients at posttreat ment was 43.2 ± 8.6 years. Patients were deemed responders to treatment if their posttreatment score on the HDRS was less than 10 or at least 50% reduced from the baseline score. Four of the 15 depressed patients did not respond to treatment by these criteria. An ad ditional group (n = 4) of patients meeting RDC for generalized anxiety disorder were also recruited into the study, but because of their small number, they were not used for statistical comparisons. Among the anxi ety patients there were three females and one male with an overall age 36.3 ± 8.4 years. Patients with general ized anxiety disorders were studied prior to treatment and, in addition to anxiety, they displayed a slight level of depression (HDRS = 11.0 ± 2.9).
Aggregation Measurements
Platelet-rich plasma (PRP) was prepared by centrifu gation at 280 x g for 10 minutes at room temperature. The red cell pellet was recentrifuged at 2,000 x g for 15 minutes to obtain platelet-poor plasma (PPP). Plate lets were counted with a Coulter ZM counter and a model 256 channelizer (Coulter Electronics, Hialeah, FL) and the PRP was adjusted to 1.8 x 108 platelets/ml with PPP. Aliquots of PRP (0.25 ml) were placed in glass reaction tubes, gently gassed for 10 seconds with 5% C0 2 /95% 0 2 , and sealed with paratilm. The samples remained sealed, except briefly during additions, until the stirring was initiated in the aggregometer. A plate let aggregometer (model PICA; Chrono-log Corp., Havertown, P A) was used to measure aggregation (Feinman et al. 1985) . Prior to the addition of epineph rine, the PRP had been preincubated with 1 mmollL aspirin for 20 minutes at 37°C to inhibit platelet cyclo oxygenase and the second wave of aggregation (Motul sky et al. 1986 ).
Unstirred PRP was preincubated for 0 to 60 minutes at 37°C with 20 IlmollL epinephrine. Aggregations were initiated by adding a stir bar to each cuvette and stir ring at setting No. 12 on the aggregometer. Light trans mittance through untreated PRP was set at 0% and that through PPP at 100%. Measurements of the extent and rate of aggregation were obtained by measuring "pri mary" aggregations, defined by the point where the ag gregatory response to 20 IlmollL epinephrine (in the presence of aspirin) deviated from a straight line on the chart recorder. Only primary aggregations are directly linked to the a2-adrenoceptor (Motulsky et al. 1986) . A drop of 100 chart units indicated maximal aggrega tion (chart speed = 1 cm/min). The time from prepara tion of each PRP sample until the tirst addition of epi nephrine was in no case less than 40 minutes, and the whole experiment (in duplicate) was accomplished within 3 hours of preparing the PRP. During this period, epinephrine-initiated aggregation measurements were made without preincubations to control for possible changes in the response during this period. In no case was there any change in the epinephrine-initiated plate let aggregation parameters during the first 110 minutes after preparation of the PRP, unless the platelets had been preincubated with epinephrine. However, with about half the samples there was a noticeable decline during longer storage times, even in the absence of epi nephrine preincubation. This decline had been previ ously reported (Rossi and Louis 1975) and indicates a decline in platelet viability during long storage times. In such cases where this was noted, we utilized only the values from the tirst, unaffected, experimental period for the data analysis. Otherwise all values were taken from the average of repeated measures.
Radioligand Binding
The preparation of puritied plasma membranes from platelets has been previously described (Piletz et al. 1990) . Saturation binding assays (20 points each) were performed in duplicate using pl25I-clonidine (New En gland Nuclear, Boston, MA) in concentrations from 0.01 NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.1 to 10 nmoliL. The reactions consisted of 0.25 ml volumes of 0.015 mg plasma membrane protein, 5 mmol Hepes, 0.5 mmol MgCh, 0.5 mmol EGTA, pH 7. 4 (adjusted with 0.1 mmol NaOH). The p1 2 5I-clonidine (New En gland Nuclear) was isotopically diluted with unlabeled p-iodoclonidine (Research Biochemicals, Natick, MA) to 440 Ci/mmole. Specific binding at a2-adrenoceptors was determined by subtracting total binding from that observed in the presence of 10 IlmollL norepinephrine. Specific binding to nonadrenergic-binding sites was de termined as the additional binding displaced by an im idazoline compound, either 10 IlmollL clonidine or 10 IlmollL moxonidine. Moxonidine was the gift of Dr. Siegfried Schafer (Solvay Pharma Corporation, Han nover, Germany). Reactions were conducted for 60 minutes at 21°C and terminated by rapid tiltration. Ra dioactivity trapped on the tilters was counted for 10 minutes per sample in a liquid scintillation counter with 71 % efficiency (Piletz et al. 1991b ). The a2-adrenoceptor binding (specific binding ± norepinephrine) and the non adrenergic-binding (additional specific binding ± the imidazoline compound) sites were quantified using a LIGAND computer-assisted two-site tit (McPherson 1985; Piletz et al. 1992 ).
Data Analysis
Data from the initial epinephrine-initated platelet aggre gations (initial extent and rate without desensitization) were directly used for statistical comparisons between subject groups, without transformation. However, the desensitization of aggregation data was first expressed as a percent of the maximal extent or maximal rate of epinephrine-intiated aggregation obtained in platelets prior to preincubation with epinephrine (i.e., the per· cent of pre-desensitized aggregation). A time course for the desensitization of each subject was constructed and modeled by a one-component exponential decayal . gorithm (GraphPAD Software, San Diego, CA). Thus, the half-time (Ph) and extentmax (after 60 min) of desensitization were derived from both of the aggre gation parameters (rate and extent) for each subject. Ad· ditional parameters that were analyzed included the density (Bmax) and affinity (Kd) values for pl25J_ clonidine binding sites, the plasma catecholamine con· centrations, and the clinical rating scores. Student'sl tests, along with repeated-measures analysis of vari ance, were used to test for statistical differences and correlations (SAS/STAT, 1989) . For each test, we ex· amined whether the variables were normall y dis tributed, and then we determined whether targetvari abIes were related to possible confounders (age, sex;.
Bonferroni p values were used to adjust for multiple comparisons. Multiple regression analyses were per. formed for each target variable with subject's age, sex. and plasma noradrenaline concentration as covariates.
!ecause there were only four nonresponders to treat �t, we did not perform separate analyses on those p!lients. However, statistical comparisons were per ilmed by ex cluding the nonresponders from the total piie nt grou p, as well as the selected patients taking Clllai n medications, and in no case did this alter the IlJIibcance of any of the fIndings; therefore, only the IZ5UIts from the overall depressed patients group are fiIIO rted. The data are expressed as the mean plus or liIus standard deviation.
RESULTS
Ases ofthe healthy subject group (36.6 ± 8.5 years)
IItfeslightly younger than those of the depressed pa �ts(42.5 ± 11.4 years) (p � .05). However, males and kmales were of approximately equal age among the .t gro ups (see under Methods). Moreover, there liS no effect of age or gender on any of the variables arasured. Among the depressed patients, the severity sfdepression as measured by the HDRS was 25.6 ± l4.Mtertreatment with desipramine, the HDRS rat ilsscale for depressed patients was 11.4 ± 9.4. This email improvement in HDRS scores following treat lien! was statistically signifIcant (p = .0001).
In the absence of epinephrine preincubation (i.e., mdesensitized), we observed no signifIcant diff erences ntither the extent or the rate of platelet aggregation Delayed Desensitization in Depression 59 between depressed patients, healthy subjects, and anxi ety patients (Table 1 ). In keeping with this, neither the Kd nor the Bmax of p125I-clonidine binding at the plate let a2 -adrenoceptor were signifIcantly different between the untreated diagnostic categories (Table 1) . Further more, there were no statistically signifIcant effects of the 6-to 8-week treatment with desipramine on un desensitized epinephrine-initiated aggregation param eters. There was, however, a marginal decline (p = .08) in the Bmax for a2-adrenoceptor binding in depressed patients following treatment (Table 1) . No signifIcant changes were noted in the a2-adrenoceptor Kd follow ing treatment. These results thus indicate no changes in the high-affinity state of the platelet a2-adrenoceptor in depression, at least in undesensitized platelets.
We next measured desensitized platelet aggrega tory responses to epinephrine throughout a 0.5-to 60-minute preincubation period, in vitro. A typical pat tern of the responses to epinephrine desensitization of aggregation from a healthy subject is shown in Figure  1 . Desensitization parameters for both the rate and ex tent of aggregation were computed. Because the two measures were highly concordant, in the interest of space we present analyses on only the desensitization of extent of aggregation data.
Whereas the aggregation of nonpreincubated plate lets was comparable in depressed patients and healthy controls (Table 1) after epinephrine desensitization, the subsequent aggregations were higher in depressed pa- Aggregation values were obtained from chart recordings as shown in Figure 1 prior to desensitiza tion (i.e., 0 min.). Minutes tients than in healthy subjects (Fig. 2) . The higher aggre gations for patients were statistically signifIcant at 4, 20, 30, and 60 minutes after preincubation with epi nephrine (60 minutes = Emax) (Fig. 3) . As can be seen in Figure 2 , after only 4 minutes of preincubation with epinephrine, the aggregation values from the healthy controls were clustered around 60% of the pre-desen sitized aggregation extents. With depressed patients the values were clustered around 75% of the pre-desen sitized aggregation extents. Interestingly, four non responders as well as three patients who were subse quently discontinued from desipramine treatment due to adverse treatment side effects were among those pa tients with the values closest to control levels (Fig. 2) . Following treatment of patients with desipramine, desensitization still tended to be less in patients than in healthy subjects, but it was not statistically signilicant (Fig. 2) . Thus epinephrine appeared to desensitize platelet aggregation less in depressed patients than in healthy subjects. A blunted desensitization of aggregation in de pressed patients appeared to result from a delayed on set of desensitization during the fIrst 0. 5 to 2 minutes after epinephrine preincubation (Fig. 3 insert) . There after, in the 2-to 60-minute preincubation cases, the overall desensitization rate was not different in de pressed patients compared to controls. Desensitization over the entire 2-to 60-minute preincubation periods yielded Ph = 11.3 ± 8.0 minutes in untreated depressed patients, versus Ph = 18.9 ± 16.6 minutes in healthy subjects (NS, p > .05).
Concentrations of plasma catecholamines were found to exist within normal ranges among our un treated subject groups (Table 1 ). The only signifIcant fInding with catecholamines was that norepinephrine concentrations were elevated during desipramine treat ment (Table 1) . However, none of the plasma catecholamine concentrations were found to be correlated with any of the aggregation or radioligand binding values.
Although the emphasis of this study was primar· ily on epinephrine-initiated aggregation, we also mea· sured the Bmax of nonadrenergic Imidazoline-binding sites (putative h) on platelets. The radioligand-binding assay could readily discriminate hand a2-adreno ceptor sites. Surprisingly, we observed an elevation in p125I-clonidine binding to the nonadrenergic Imidazo line h site in depressed patients despite no change in Desensitization Time (Min)
�3. Comparison of the desensitization time courses observed in depressed patients and healthy subjects. Data from
Incings of each subject were obt ained as in Figure 1 and quantitated as described in Table 2 and Methods. Values represent Ibtpercent of the initial aggregation extent (i.e., at 0 mi nutes of preincubation with epinephrine) from depressed patients prior to treatm ent (0-0), depressed patients aft er treatment for 6 weeks with desipramine ( .... .. .. .. ), and healthy control IUbjects (0---0). Asterisks indicate the times of preincubation at which statistical differences (p � .05) were observed be twee n untreated pat ients and healthy subjects. Curves were fIt by a monoexponential decay algorithm. Insert: Smooth lines
If!re ht to the same data as shown in the larger fIgure to indicate differences in the shape of desensitization between depressed pilients and healthy subjects; emphasizing an apparent delay in depressed patients at the outset of desensitization during short-time (0 to 2 minute) preincubations with epinephrine.
l2-adrenoceptor sites (Table 1) . Moreover, the Bmax for !he nonadrenergic II site declined following treatment fA the patient group (Table 1) . This rather robust in crease in h sites in depression (p < .005) might explain our previous positive fIndings of increased 3H-amino cbUdine binding in depression (Piletz et al. 1990 (Piletz et al. , 1991 CIlIII pared to no change in a2-adrenoceptors observed it this study. Our earlier reports lacked the sensitivity kl completely distinguish a2-adrenoceptors from II s*s (discussed in Piletz et al. 1990 Piletz et al. , 1991 ; therefore, 1\ upregulation of binding in depression may have IImt solely due to II sites misidentifIed as a2-adreno uptors. However, the nonadrenergic measurement of fl-donidine binding to II sites (Kd or Bmax) did not arre late with epinephrine-initiated platelet aggrega1iIn, in keeping with the reported low affinity of II iRs for epinephrine (Piletz et a1. 1992 ).
Next we attempted to determine whether corre IIIio ns existed between the measured variables. Sur prisingly, with undesensitized platelets, we failed to Gbtain any signifIcant correlations between epineph rile-initiated aggregation and a2-adrenoceptor density; only a weak but nonsignifIcant correlation existed be tween the extent of aggregation and the a2-adreno ceptor Bmax (for all subjects r = 0.203, P = .241). A simi lar nonsignifIcant correlation was also found between the extent of undesensitized aggregation and the II Bmax (for all subjects r = 0.24, P = .19). No other trends were observed among the undesensitized aggregation parameters in any diagnostic groups. Furthermore, the undesensitized aggregation parameters were not cor related with any of the subsequent desensitization parameters. However, a signifIcant correlation was ob served between the maximum extent of desensitization in response to epinephrine and the Bmax for the high affInity state platelet a2-adrenoceptor. Figure 3A demonstrates this correlation for all subjects (r = 0.479, P = .02). This correlation remained statistically sig nifIcant (p � .05) among just the depressed patients (as seen in the open circles of Fig. 3A) . Because of the large number of variables in this study, any single correla tion might represent a type I statistical error. However, no correlations were found between any of the other desensitization of aggregation parameters and the other variables, including the nonadrenergic It site radio ligand-binding parameters (Fig. 3B) .
Following 6 to 8 weeks of treatment with desipra mine, platelets were recollected from a subgroup of 15 depressed patients and reanalyzed for desensitization NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.: in vitro. The results were equivocal regarding a possi· ble normalization in the desensitization of aggregatiol parameters following treatment. In treated patients, the extent of desensitization was no longer different in p� tients compared to healthy subjects, suggesting a nor· malization (Figs. 2 and 3, closed diamonds) . However, with regard to the rate of desensitization, in medicated patients the rates were still higher than in healthy su� jects (p � .5 at 8 and 20 minutes), as had been observed in the untreated patients (Fig. 2) . Moreover, we o� served no association between any of the biochemical measurements and the clinical rating scales (HDRS·A or HDRS-D scores). Therefore, these results are more consistent with the possibility that blunted desensiti zation is a trait marker, rather than an index of severity for depression.
DISCUSSION
In previous studies (Piletz et al. 1990 (Piletz et al. , 1991 , we reported that platelets from depressed patients displayed el� vated 3H-p-aminoclonidine binding to high-affmi� state a2-adrenoceptors, as compared to healthy sub jects. Therefore, it was anticipated that epinephrin� initiated platelet aggregations might also be abnormall) robust in depressed patients. Our frrst attempts to dem onstrate this utilized undesensitized platelets (Fig. t "0 min"), similar in preparation to those platelets used in our earlier binding studies (Piletz et al. 1990 (Piletz et al. , 1991 .
Nevertheless, in undesensitized platelets we werewr able to detect any differences in aggregation between depressed patients and healthy subjects ( Table 1) . How· ever, as short a time as 4 minutes of desensitizationd aggregation by epinephrine revealed that the sub� quent aggregation of platelets in depressed patients WI! indeed more robust than in healthy subjects (Fig. 1) A I-hour time course of epinephrine preincubationsfur· ther revealed that the extent of in vitro desensitiza. tion of platelet aggregation in depressed patients WI! blunted (Fig. 3) . Moreover, that blunted desensitiza. tion of aggregation appeared to be consequential tOI delayed onset of desensitization during the frr st 0 t01 minutes of desensitization (Fig. 3 insert) . Therefore, 0\111 data emphasize a2-adrenoceptor dysregulatory p� nomena in depression, rather than a simple steady-staE. alteration.
Our failure to observe steady-state differences in aggregation is at odds with Garcia-Sevilla et al. (lCJiXll who reported potentiation of epinephrine-initiatl'C platelet aggregation in depressed patients using \III'" desensitized platelets. One difference between OLJ studies is that Garcia-Sevilla et al. (1990) used low! epinephrine concentrations (i.e., 1 \!mol) to initi� aggregation rather than the 20-\!mol concentration thaI we used. However, another difference is that our sub leets rested in the supine position prior to the blood drawing, whereas the subjects reported by Garcia Sevilla et al. (1990) did not. Since desensitization of platelet ep inephrine-initiated aggregation has been shown to occur in vivo after short-time infusions of epi nephrine (Jones et al. 1986; Hamilton et al. 1987) , sym pathetic or adrenal output into the blood might desen sitize the platelet a2-adrenoceptor. Elevations in plasma cdtecholamines occur in some individuals as a conse quence of anticipatory stress prior to blood giving. Therefore, orthostatic changes in circulating catechola mines might be considered as another factor in the study of Garcia-Sevilla et al. (1990) , which could have actu ally desensitized their subjects' platelets in vivo. If that were the case, then our data (Fig. 2) would be entirely wnsistent with their data.
Presynaptic a2-adrenoceptors provide feedback in hibitory co ntrol over the vesicular release of norepi nephri ne (Langer 1981) . Siever and Davis (1985) have put forward the "dysregulation hypothesis of depres sIOn " based on evidence that the regulation of nor adrenaline release is "inadequately buffered" in depres �n. Briefl y summarized, that evidence is twofold: (A) plasma noradrenergic metabolite concentrations have bee n shown to be typically more variable in depressed patients than in healthy subjects under basal conditions (Gwirtsman et al. 1989) , and (B) changes in diet or ac li\ity appear to cause alterations in the excretion of nor tpinephrine metabolites in depressed patients that do ootoccurin healthy individuals (Muscettola et al. 1984; Good e et al. 1973; Beckmann et al. 1979 ). Thus, Siever iII d Davis (1985) have further suggested that a dysregu liled a2-adrenoceptor might underlie these findings such that "depressed patients display reduced respon siwness to discrete, appropriate stimuli." In fact, such statements might have been used to accurately describe our hnding of blunted desensitization to epinephrine tlimulation of the platelet a2-adrenoceptor. In this con text, our data therefore extend the contention put forth by Siever et al. (1987) that a2 -adrenoceptor d ysregula �, such as blunted desensitization, might underlie depression.
Our aggregation measurements were performed in the unique plasma obtained from each individual, which contained endogenous catecholamines. There be, we sought to determine whether a blunted desen sitization of the a2-adrenoceptor in depression might blcorrelated with, and therefore of secondary impor &1nce to, changes in concentrations of plasma catechol lIIlin eS. However, we found no difference between the llll lre ated diag nostic groups in their plasma catechol lIIlin econcentrations (Table 1) . Similarly, three earlier iludies have also failed to detect differences in plasma IOrepinephrine concentrations in depressed patients Delayed Desensitization in Depression 63 (Sevy et al. 1989; Siever et al. 1984; De Villiers et al. 1989) . Therefore, it appears unlikely that the blunted desensitization observed in depressed patients at pre treatment could be explained by lowered catecholamine concentrations in plasma. However, since posttreat ment plasma norepinephrine concentrations were elevated (Table 1) , a possibility exists that the partial normalization of the blunting observed after desipra mine treatment could relate to norepinephrine. Further investigations will need to be performed to determine if blunted desensitization is a state or trait marker for depression.
An intrinsic factor within the platelet should also be considered to possibly underlie the blunted a2-adrenoceptor desensitization in depression at pretreat ment. One candidate for that intrinsic factor might be G-proteins, because these regulatory proteins are in volved in �-adrenoceptor desensitization (Sibley and Lefkowitz 1985) . Evidence supporting altered G-protein concentrations in depression has been reported by Young et al. (1991) , who demonstrated that post mortem cerebral cortex Gs a subunits are elevated in bipolar affective disorder. Based on such evidence, Schreiber and Avissar (1991) have further suggested that hyperfunction of G-proteins might lead to an "un stable catastrophic system" characteristic of a manic or depressive state. Therefore, alterations in G-proteins in depression have precedent.
In the present study, we were unable to replicate our earlier results (Piletz et al. 1990 (Piletz et al. , 1991 , which demonstrated an elevation in a2-adrenergic binding of 3H-p-aminoclonidine on platelets in depression. In the present study, the binding of p1 2 5I-clonidine to plate let a2-adrenoceptors was not different in depressed pa tients compared to healthy controls (Table 1) . It is un likely that this discrepancy is due to diff erences between these radioligands because in numerous experiments designed to compare these radioligands, we have found no difference in the nature of the sites that these two analogues label (unpublished results). Moreover, pres ent results confirm a decline in a2-adrenergic binding of p1 2 5I-clonidine after desipramine treatment of pa tients (Table 1) , which is comparable in magnitude to that which we previously reported with 3H-p-amino clonidine (Piletz et al. 1991) . However, although not confirming our earlier pretreatment findings for ele vated a2-adrenoceptor binding in un desensitized plate lets from depressed patients, we observed that the density of radioligand binding to nonadrenergic Im idazoline sites (putative Imidazoline h sites) was in creased in depressed patients (Table 1) . Our earlier data (Piletz et al. 1990 (Piletz et al. , 1991 were compatible with two bind ing sites, but we did not perform two-site Scatchard plot analyses due to the lower specific activity of 3H_ p-aminoclonidine. It therefore seems conceivable that we had previously misidentifIed It sites for a.2-adreno ceptor-binding sites. Therefore, the pretreatment ele vation in the density of previously unidentifIed It sites could explain our earlier fmdings of an elevation in a.2-adrenoceptor binding in depression.
Thus, postdesensitization a.2-adrenoceptor-medi ated platelet aggregations (Fig. 2) as well as the density of nonadrenergic putative-It-binding sites (Table 1) were both elevated in depressed patients compared to healthy subjects. Obviously, this suggests that there might be some link between these phenomena. How ever, we found no correlations between the It-binding Although radioligand-binding parameters for the putative h site were not correlated with aggregation, a correlation was nevertheless observed between the density of high-affinity state a.2-adrenoceptor sites (Brnax) and the extent of epinephrine-initiated desen sitization (Fig . 3) . This correlation indicated that the greater the density of the high-affinity adrenoceptor state the less the desensitization. Unfortunately due to the relatively low number of subjects, this correlation needs to be substantiated. Nevertheless, because G-proteins are known to be coupled with high-affinity state platelet a.2-adrenoceptors, a slower desensitiza tion might also be consistent with a higher degree of coupling of G-proteins in the high-affinity adrenocep tor state.
Whether platelets provide a reliable model of the brain a.2-adrenoceptor is still an open question. In hu man brain, the principal a.2-adrenoceptor subtype (a.2A) is the same as that identifIed in human platelets (Kobilka et al. 1987; Bylund et al. 1988; Ordway et al. 1993 ) . Moreover, the density of human a.2-adreno-NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO. 1 ceptor-binding sites in platelets is under genetic (on trol (Propping et al. 1986 ) . Nevertheless, Nutt and Molyneux (1986) reported no correlation between plate let 3H-yohimbine binding and the central nervous sys· tern response to a clonidine infusion test (blood pres· sure and growth hormone response) in healthy subj ects or in subjects with panic disorder. Also, Hamilton et al. (1985) reported no correlation between platelet 3H-yohimbine binding and brain 3H-clonidine bindin g in rabbits that were treated under a variety of regula· tory conditions. Unfortunately, due to the aforemen tioned distinctions between yohimbine-(a.2-adrenergic) and clonidine-(imidazoline) binding sites, the si g nifIcance of these reports remains uncertain. Future studies will therefore be required to determine whether the expression of brain a.2-adrenoceptors is regulated similarly to that in platelets and whether desensitiza· tion is also altered in brains of depressed patients.
